Verastem Announces the Presentation of Clinical Data at iMig 2016
The primary objective from this ongoing open-label, single-center, neoadjuvant Window of Opportunity study is to evaluate tolerability, along with biomarker and tumor volume response to Verastem’s focal adhesion kinase inhibitor VS-6063 following eithe…